Article
Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
Registro en:
BORTOLINI, Miguel Junior Sordi et al. Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups. International Journal of Environmental Research and Public Health, v. 19, 1853, p. 1 - 10, 2022.
1660-4601
10.3390/ijerph19031853
Autor
Bortolini, Miguel Junior Sordi
Petriz, Bernardo
Mineo, José Roberto
Resende, Rafael de Oliveira
Resumen
Since the World Health Organization declared the global COVID-19 state of emergency in
early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have
been approved and implemented in vaccination campaigns worldwide. Although clinical trials for
these vaccines have been carried out using highly controlled methods with accurate immunological
tests, clinical questionnaires did not include questions concerning the physical activity profile among
volunteers. It has been well established that physical activity plays a pivotal role in the immune
response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept
should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong
evidence regarding the importance of analyzing physical activity parameters to improve the accuracy
of clinical trials on assessing the efficacy of vaccine candidates.